BUSINESS
Pharma wrap: WHO pushes for affordable insulin, to encourage pre-qualification of generics
Despite ample supply, insulin prices are currently a barrier against treatment in LMICs, according to WHO
BUSINESS
Aster DM expects to end FY20 with EBITDA margins in 13-14% range
“We expect to see a boost of EBITDA margins by more than 50 basis points,” Moopen said.
BUSINESS
Expect FTC nod for $900 million Sandoz deal before December: Aurobindo Pharma
The company had announced the acquisition of Sandoz's dermatology and formulations business in September last year, making it the largest outbound deal by an Indian pharma company.
BUSINESS
Exclusive | 10 years on: How govt's Rs 600cr vaccine complex failed to take-off
The government may be considering to bring in a partner in public-private partnership (PPP) mode to revive Rs 600 crore Integrated Vaccine Complex (IVC), at Chengalpattu
BUSINESS
Lupin sells Japanese business Kyowa for enterprise value of Rs 3,702.4 crore
Lupin will get net proceeds of $300 million from the sale, which will be used to pare debt and invest in core markets of US and India.
BUSINESS
Will e-pharmacy regulation see the light of day?
The government does not want to antagonise hundreds of thousands of brick and mortar or offline pharmacy store owners
BUSINESS
Cipla expects to end FY20 with gross margins of 65-66% led by new launches in second half
The EBITDA margins of Cipla stood at 20.7 percent and gross margins at 65.7 percent in Q2FY20.
BUSINESS
Lupin plans to offer Somerset, Goa plants for USFDA re-inspection by March 2020
While the Goa plant is under warning letter since 2017 for violation of current good manufacturing practices, Somerset plant was classified as official action indicated (OAI) status.
BUSINESS
Fortis Healthcare Q2: Strong recovery continues; company posts net profit of Rs 111 crore vs loss last year
Fortis reported a net loss of Rs 166.6 crore in the same period last year.
BUSINESS
Strides Shasun, Ajanta Pharma pass USFDA's ranitidine impurity test
The lab results also found that the NDMA impurity in ranitidine drugs sold by Dr Reddy’s and Aurobindo Pharma, Sanofi in beyond permissible limits.
BUSINESS
Explainer: How drug prices are regulated in India
Around 14 percent of drugs by value and 25 percent by volume fall under price controls.
BUSINESS
Dr Reddy's Chinese gamble -- build biz on early mover advantage, recent tender wins
Dr Reddy’s is the first Indian company and the second international drug company after Sandoz to be selected and win a supply tender in China under the Quality Consistency Evaluation (QCE) system.
BUSINESS
How Cipla's Umang Vohra is trying to invigorate the 84 year old company
Vohra’s first two years were spent on cutting the flab, restructuringthe business, rationalising the workforce and improving its productivity.
BUSINESS
How Wellthy Therapeutics is redefining healthcare delivery with a digital pill
The app acts as a digital personal health coach that uses technology tools machine learning and artificial intelligence to nudge the person to adopt behavioral change.
BUSINESS
Will Cequa turn the tide for Sun Pharma in US?
Sun Pharma has invested around $1 billion in the specialty business in US.
BUSINESS
Cipla looks beyond pills, keen to invest in innovations in patient care, drug delivery technologies
The company said it is interested in companies that solve unmet need in patient care, new drug delivery systems and medical records.
BUSINESS
In Singh brothers’ case, Delhi police will have to find where all the money has flown
Investigating agencies have a task at hand to find out the money trail -- where it had flown and who were the end beneficiaries
BUSINESS
Lupin plans to file Etanercept, Pegfilgrastim biosimilars in US by Q4FY20
In Europe, the second largest market for the Etanercept, Lupin is expecting approval in March 2020, and plans to commercialise it by Q1FY21.
BUSINESS
Nobel Prize: How 2019's winners are revolutionising medicine
The 2019 Nobel Prize in Physiology or Medicine has been awarded jointly to three physician-scientists for their discoveries of how cells sense and adapt to oxygen availability.
BUSINESS
Shivinder, Malvinder Singh arrest: SEBI report lays bare sordid tale of siphoning at Religare
SEBI in a March order directed Religare Enterprises and its subsidiary to recover funds to the tune of Rs 2,315.09 crore that had been diverted to various entities for the ultimate benefit of erstwhile promoters of REL
BUSINESS
Indian pharma market sees growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
BUSINESS
Delhi-based startup Agatsa reshaping cardiac care with low cost portable ECG devices
The device costs just Rs 4,000 after discounts on popular e-commerce platforms. The low cost of the device and negligible operating costs will enable clinics to offer ECG for free as a point-of-care (PoC) diagnostic test.
BUSINESS
Exclusive: Aurobindo Pharma promoters open new front in Continental Hosp founder vs IHH Healthcare fight
The Aurobindo family will fund gastroenterologist Gurunath Reddy buy out stake held by IHH Healthcare, and ring-fence Continental Hospitals from other prospective buyers.
BUSINESS
Pharma wrap: No respite for Glenmark, USFDA’s warning letter on Baddi facility adds to woes
The warning letter comes at a time when the company has been struggling with high debt and lack of meaningful approvals for products that can shore-up declining US sales
